BTIG Downgrades Eidos Therapeutics (EIDX) to Neutral
Tweet
Share
E-mailGet Alerts EIDX Hot Sheet
Price: $122.21 --0%
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BTIG analyst Thomas Shrader downgraded Eidos Therapeutics (NASDAQ: EIDX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Eidos Therapeutics click here. For more ratings news on Eidos Therapeutics click here.
Shares of Eidos Therapeutics closed at $79.65 yesterday.
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Northcoast Downgrades Brinker Int'l (EAT) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
